Plain-English translation of NCT07579936 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing SAL056, a bone-strengthening medication given as an injection, in women who have gone through menopause and have weak bones (osteoporosis). Researchers want to find the best dose and schedule for this new treatment. About 200 women will receive different combinations of this medication over 8 weeks to compare safety and effectiveness.
Postmenopausal women often develop weak bones that fracture easily because hormone changes affect bone health. This medication may help rebuild bone strength, but doctors need to find the safest and most effective way to give it.
You likely qualify if…
You likely don't qualify if…
You will visit the hospital about 7 times over approximately 13 weeks. First, there's a screening visit (up to 4 weeks) where blood work and medical history are reviewed. Then, you'll receive injections of the medication weekly or twice weekly for 8 weeks, depending on which group you're assigned to. Some groups will also receive an initial 2-4 week course of another medication before switching to the new treatment. Finally, you'll have a follow-up visit one week after treatment ends to check for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China